Skip to main content

Table 3 First-choice drugs and combined protocols chosen by respondents for the treatment of proteinuria in the clinical scenarios of CanL stages IIb, III and III

From: Dogs with leishmaniosis: how are we managing proteinuria in daily practice? A Portuguese questionnaire-based study

First-choice drugs and combined protocols LeishVet classification
Stage IIb (n = 14) Stage III (n = 54) Stage IV (n = 76)
a. First-choice drugsa
 ACEI 14 (100%) 46 (85.2%) 60 (78.9%)
 ARB 0% 5 (9.3%) 10 (13.2%)
 CCB 0% 2 (3.7%) 4 (5.3%)
 Antithrombotic therapy 0% 1 (1.9%) 2 (2.6%)
b. Single-drug and combined protocolsb
 ACEI 9 (64.3%) 22 (40.7%) 35 (46.1%)
 ACEI + NA 4 (28.7%) 7 (13.0%) 0%
 ACEI + aldosterone receptor blockers 0% 1 (1.9%) 1 (1.3%)
 ACEI + antithrombotic therapy 0% 6 (11.1%) 11 (14.5%)
 ACEI + ARB 1 (7.1%) 4 (7.4%) 9 (11.8%)
 ACEI + CCB 0% 2 (3.7%) 3 (3.9%)
 ACEI + ARB + antithrombotic therapy 0% 0% 3 (3.9%)
 ACEI + CCB + aldosterone receptor blockers 0% 0% 1 (1.3%)
 ACEI + other 0% 5 (9.3%) 2 (2.6%)
 SUM (ACEI with other compounds) 1 (7.1%) 18 (33.3%) 30 (39.5%)
 ARB 0% 4 (7.4%) 6 (7.9%)
 ARB + antithrombotic therapy 0% 1 (1.9%) 1 (1.3%)
 CCB 0% 0% 4 (5.3%)
 CCB + NA 0% 2 (3.7%) 0%
 SUM (protocols without ACEI) 0% 7 (12.9%) 11 (14.5%)
  1. ACEI angiotensin converting enzyme inhibitors angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CCB Calcium channel blockers, NA no answer/not detailed
  2. aOnly one option available
  3. bOne or more options available